Buel Rodgers
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2017First federal award
$9.0MFederal grants as PI14 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
14 awards · $9.0M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 5, 2025 | NIH | SBIR Phase I Preclinical validation of AVGN7 for treating obesity and type 2 diabetes mellitus. | $350K | AAVOGEN INC |
| Jul 12, 2024 | NIH | SBIR Phase I Development of optimized adeno-associated viral capsids for muscle gene therapy | $134K | AAVOGEN INC |
| Aug 16, 2023 | NIH | SBIR Phase II Preclinical Development of a Novel Gene Therapeutic for Inclusion Body Myositis | $974K | AAVOGEN INC |
| Aug 2, 2023 | NIH | SBIR Phase I Development of optimized adeno-associated viral capsids for muscle gene therapy | $140K | AAVOGEN INC |
| Aug 2, 2023 | NIH | SBIR Phase I Development of optimized adeno-associated viral capsids for muscle gene therapy | $140K | AAVOGEN INC |
| Sep 30, 2022 | NIH | SBIR Phase II Preclinical Development of a Novel Gene Therapeutic for Inclusion Body Myositis | $1.9M | AAVOGEN INC |
| Sep 23, 2022 | NIH | SBIR Phase II Preclinical Development of a Novel Gene Therapeutic for Inclusion Body Myositis | $904K | AAVOGEN INC |
| Feb 26, 2021 | NIH | SBIR Phase II AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia | $135K | AAVOGEN INC |
| Sep 5, 2019 | NIH | SBIR Phase II AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia | $1 | AAVOGEN INC |
| Sep 1, 2019 | NIH | SBIR Phase I Preclinical Validation of AVGN7 for Treating Duchenne Muscular Dystrophy | $225K | AAVOGEN INC |
| Aug 19, 2019 | NIH | SBIR Phase I Preclinical Validation of AVGN7 for Treating Duchenne Muscular Dystrophy | $225K | AAVOGEN INC |
| Aug 31, 2018 | NIH | SBIR Phase II AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia | $660K | AAVOGEN INC |
| Sep 25, 2017 | NIH | SBIR Phase II AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia | $1.2M | AAVOGEN INC |
| Sep 25, 2017 | NIH | SBIR Phase II AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia | $2.0M | AAVOGEN INC |
Peer ranks
Federal funding#89
Awards as PI#57
Patents#273
Companies
- AAVOGEN INCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.